Advertisement
U.S. markets close in 2 hours 36 minutes
  • S&P 500

    5,250.07
    +1.58 (+0.03%)
     
  • Dow 30

    39,753.38
    -6.70 (-0.02%)
     
  • Nasdaq

    16,372.73
    -26.79 (-0.16%)
     
  • Russell 2000

    2,127.87
    +13.52 (+0.64%)
     
  • Crude Oil

    82.81
    +1.46 (+1.79%)
     
  • Gold

    2,240.30
    +27.60 (+1.25%)
     
  • Silver

    24.93
    +0.18 (+0.72%)
     
  • EUR/USD

    1.0800
    -0.0029 (-0.27%)
     
  • 10-Yr Bond

    4.1980
    +0.0020 (+0.05%)
     
  • GBP/USD

    1.2626
    -0.0012 (-0.10%)
     
  • USD/JPY

    151.3530
    +0.1070 (+0.07%)
     
  • Bitcoin USD

    70,591.82
    +1,335.12 (+1.93%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

CLASS ACTION UPDATE for XENT, FDX and CTST: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / July 12, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the lead plaintiff deadlines listed below to petition the court, and those interested in their eligibility are encouraged to contact the firm. There will be no cost or obligation to you.

Intersect ENT, Inc. (XENT)

Lawsuit on behalf of: investors who purchased August 1, 2018 - May 6, 2019
Lead Plaintiff Deadline : July 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intersect-ent-inc-loss-form?prid=2356&wire=1.

According to the filed complaint, during the class period, Intersect ENT, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect’s sinus implant; (2) Intersect’s sales force would focus on ensuring reimbursement; (3) Intersect’s sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect’s SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants’ positive statements about Intersect’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

FedEx Corporation (FDX)

Lawsuit on behalf of: investors who purchased September 19, 2017 - December 18, 2018
Lead Plaintiff Deadline : August 26, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fedex-corporation-loss-form?prid=2356&wire=1.

According to the filed complaint, during the class period, FedEx Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) TNT’s overall package volume growth was slowing as TNT’s large customers permanently took their business to competitors after the Cyberattack; (2) as a result of the customer attrition, TNT was experiencing an increased shift in product mix from higher-margin parcel services to lower-margin freight services; (3) the anticipated costs and timeframe to integrate and restore the TNT network were significantly larger and longer than disclosed; (4) FedEx was not on track to achieve TNT synergy targets; and (5) as a result of these undisclosed negative trends and cost issues, FedEx’s positive statements about TNT’s recovery from the Cyberattack, integration into FedEx’s legacy operations, customer mix, customer service levels, profitability, and prospects lacked a reasonable basis.

CannTrust Holdings Inc. (CTST)

Lawsuit on behalf of: investors who purchased November 14, 2018 - July 5, 2019
Lead Plaintiff Deadline : September 9, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/canntrust-holdings-inc-loss-form?prid=2356&wire=1.

According to the filed complaint, during the class period, CannTrust Holdings Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) the Company’s Pelham greenhouse did not comply with certain regulations; (3) as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/551739/CLASS-ACTION-UPDATE-for-XENT-FDX-and-CTST-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Advertisement